Systemic thrombolysis and anticoagulation improved biomarker measurements in massive-like pulmonary embolism and severe COVID-19 pneumonia: a case report

Hector Betancourt-del Campo 1,2, Carlos Jerjes-Sanchez 1,2*, Mauricio Castillo-Perez 1, Hector López-de la Garza 1,2, José Gildardo Paredes-Vázquez 1,2, Yoezer Z Flores-Sayavedra 1, Francisco Moreno-Abril Hoyos3, and Marcos Ibarra-Flores3

1 Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud. Monterrey, Nuevo Leon, Mexico; 2 Instituto de Cardiologia y Medicina Vascular, TecSalud, San Pedro Garza Garcia, Nuevo Leon, Mexico; and 3 Hospital Zambrano Hellion, TecSalud, San Pedro Garza Garcia, Nuevo Leon, Mexico

Received 1 July 2020; first decision 21 July 2020; accepted 4 November 2020; online publish-ahead-of-print 13 December 2020

Background From asymptomatic patients to severe acute respiratory distress syndrome, COVID-19 has a wide range of clinical presentations, and venous thromboembolism has emerged as a critical and frequent complication.

Case summary We present a case of a 69-year-old man with a clinical presentation of massive-like pulmonary embolism (PE) overlapping with severe COVID-19 pneumonia. The diagnosis was made based on hypotension, severe oxygen desaturation (33%), and right ventricular dysfunction (RVD). We used alteplase and low-molecular-weight heparin, obtaining immediate clinical improvement. Also, we identified an extremely elevated D-dimer (31.2 mcg/mL), and computed tomography pulmonary angiography (CTPA) revealed an unexpected low thrombus burden and a crazy-paving pattern. Considering this, we decided to discontinue the alteplase. Therefore, the mechanisms of pulmonary hypertension and RVD could be multifactorial. Despite the patient’s respiratory status worsening and ongoing mechanical ventilation, biomarkers kept lowering to normal ranges. It appears a favourable outcome was related to early PE diagnosis and a multimodal therapeutic approach.

Discussion Physicians in the ER should be warned about extremely high D-dimer measurements and severe oxygen desaturation as possible markers of severe COVID-19 pneumonia in patients with high-clinical suspicion of PE. Although ESC guidelines recommend immediate reperfusion in cardiogenic shock secondary to PE, we suggest initial CTPA in patients with high-clinical suspicion of severe COVID-19.

Keywords Case report • COVID-19 • SARS-CoV-2 • Pulmonary embolism • Thrombolysis

* Corresponding author. Tel: +528188880464. Email: jerjes@prodigy.net.mx, carlos.jerjes@udicem.org.mx, carlos.jerjes@medicos.tecsalud.mx

Handling Editor: Richard Alexander Brown
Peer-reviewers: Alberto Bouzas-Mosquera and Rajiv Rampat
Compliance Editor: Max Sayers
Supplementary Material Editor: Ross Thomson
© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Primary Specialties involved other than cardiology

Cardiology, Pneumology and Critical Care Medicine, Infectology

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was discovered in Wuhan, China, in late 2019, and coronavirus disease 2019 (COVID-19), the disease caused by SARS-CoV-2, rapidly evolved into a global pandemic. COVID-19 is characterized by high mortality predominantly in male patients secondary to severe acute respiratory distress syndrome. However, among common complications observed in deceased patients with COVID-19 disease, venous thromboembolism has emerged as a critical and frequent complication. Currently, most of the data regarding this clinical association has been derived from hospitalized patients. Data on the clinical presentation, therapeutic approach, and biomarkers behavior in outpatients are scarce. Here we present the case of a 69-year-old man with a clinical presentation of massive-like pulmonary embolism (PE) overlap with severe COVID-19 pneumonia in whom we observed immediate clinical improvement using a reduced alteplase dose. Additionally, we identified an unusual D-dimer (DD) measurement, multifactorial mechanisms of pulmonary hypertension, and upon admission, despite severe right ventricular dysfunction, a borderline B-type natriuretic peptide (BNP) value.

Timeline

| Time                 | Events                                                                                       |
|----------------------|-----------------------------------------------------------------------------------------------|
| Medical history      | Hypertension, chronic obstructive pulmonary disease (COPD), obstructive sleep apnoea, arthritis, morbid obesity |
| 27 days prior to admission | Contact with SARS-CoV-2 (+) son                                                             |
| Initial presentation | Clinical instability, oxygen desaturation (33%)                                           |
| On arrival to the ER | Electrocardiogram: sinus tachycardia, S1Q3T3, qR, ST-elevation in V1 and aVR               |
|                      | Chest X-ray: bilateral ground-glass opacity                                                  |
|                      | Transthoracic echocardiogram: severe right ventricular dysfunction                          |
|                      | Biomarkers: D-dimer 31.2 mcg/mL, B-type natriuretic peptide (BNP) 101 pg/mL, hs-cTnI 49.7 mcg/L |

Case presentation

A 69-year-old man presented to the Emergency room (ER) with a 2-h history of stabbing pain in the right lower limb, associated with sudden dyspnea, plus severe chest pain 6/10, presyncope, and profuse diaphoresis. His past medical history included former smoking, hypertension
valsartan, hydrochlorothiazide, and atenolol), chronic obstructive pulmonary disease (non-specified treatment), obstructive sleep apnoea syndrome treated with continuous positive airway pressure (CPAP), undifferentiated arthritis (sulfasalazine and acemetacin), and morbid obesity. Additionally, his son had been recently diagnosed with severe COVID-19 after a recent trip to Vail, Colorado, 31 days ago, and they had contact in Mexico City 27 days before his admission. On arrival at the ER, the patient was febrile, with clinical instability, hypotension (80/50 mmHg), tachycardia (140 b.p.m.), respiratory failure (30 b.p.m.), and severe oxygen desaturation (33%). The physical examination revealed a stuporous patient with pallor, diaphoresis, loud S2, bilateral lung crackles, swollen feet, and a body mass index (BMI) of 42.1 kg/m². We started oxygen with a reservoir mask at 10 L/min, improving consciousness state, oxygen saturation (73%), and heart rate (HR) (110 b.p.m.).

The initial electrocardiogram (ECG) showed sinus tachycardia at 110 b.p.m., right axis deviation, QTc 471 ms, S1Q3T3 pattern, presence of qR, ST-elevation in V1 and aVR, inferior pseudonecrosis, and right ventricular systolic overload (Figure 1A). A chest X-ray showed bilateral ground-glass opacity, and pulmonary infiltrates (Figure 2). A transthoracic echocardiogram revealed severe right ventricular dysfunction and hypokinesis, left ventricular ejection fraction (LVEF) of 80% by the Teicholz method, tricuspid annular plane systolic excursion (TAPSE) 9 mm, tricuspid regurgitation gradient of 28 mmHg, and pulmonary artery systolic pressure (PASP) of 48 mmHg (Video 1). Blood tests showed haemoglobin 14.6 g/dL (13.2–18.0 g/dL), 11.6 \times 10^9/\mu L leucocytosis (4.5–11.0 \times 10^9/\mu L), lymphocytes 700 per mm³ (1000–4000 per mm³), platelets 323 \times 10^9/\mu L (150–420 \times 10^9/\mu L), glucose 242 mg/dL (60–100 mg/dL), creatinine 1.3 mg/dL (0.7–1.3 mg/dL), hypoalbuminaemia 2.6 g/dL.
We decided to commence treatment using alteplase with a 10 mg bolus, followed by 40 mg in 2 h and enoxaparin 80 mg BID. The computed tomography pulmonary angiography (CTPA) revealed a dilated main pulmonary artery (34 mm) and the presence of thrombus located in the right interlobar artery and the segmental branches of the superior left lobe and inferior left and right lobes (Figure 3). Unexpectedly, the lung parenchyma revealed a crazy-paving pattern, highly suggestive of severe COVID-19 pneumonia (Figure 4). Immediately after the 10 mg alteplase bolus, consciousness state, blood pressure (120/85 mmHg), HR (100 b.p.m.), and respiratory rate (25 b.p.m.) improved. Severe oxygen desaturation remained low (75%) despite using a reservoir oxygen mask at 10 l/min. Considering the thrombus burden and severe pneumonia, we decided to discontinue the 40 mg alteplase infusion and transfer the patient to the COVID-19 isolated ICU. To protect the patients and healthcare workers, we used a telepresence robot for daily interaction. The rapid nucleic acid amplification test for influenza A and B was negative. We collected samples following Center for Disease Control and Prevention (CDC) guidance (serum, and nasopharyngeal and oropharyngeal swab specimens). The patient received enoxaparin 80 mg BID, oral hydroxychloroquine 200 mg thrice in a day (TID), azithromycin 500 mg QD, IV ceftaroline 1 g QD, oral lopinavir/ritonavir 200/50 mg BID, and IV paracetamol 1 g TID.

On Day 2, the patient remained mostly stable. Upon follow-up examination, hs-cTnI and BNP increased, and D-dimer decreased (Figure 5). A chest X-ray reported a slight improvement of bilateral ground-glass opacity and pulmonary infiltrates. The nasopharyngeal and oropharyngeal swabs tested positive for SARS-CoV-2 by real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) assay.

On Day 3, due to respiratory failure and diagnosis of acute respiratory distress syndrome (ARDS) we started invasive mechanical ventilation (FiO2 70%, PEEP 16, and Kirby index of 105). The patient had hypotension as a side effect of sedation, which required transient inotropic support (norepinephrine). For the mechanical ventilation, we used A/C mode, with lung-protective ventilation using tidal volumes of 6 ml/kg predicted body weight and inspiratory pressure of 12 cmH2O. We maintained an initial respiratory rate (RR) 16 b.p.m., I:E relation of 1:1.5, and a constant PEEP of 16 cmH2O with decremental titration. We provided prone ventilation, and we did not use recruitment manoeuvres. Despite clinical worsening, the biomarkers continued to improve (Figure 5). We stopped hydroxychloroquine due to abnormal QTc (up to 560 ms) on follow-up ECG (Figure 1B). We administered three doses of tocilizumab 800 mg TID and continued full anticoagulation with enoxaparin. We maintained the norepinephrine support intermittently for nine days.

On Days 5 through 8, due to clinical worsening and the high viral load, we administered three doses of hyperimmune plasma each day, with improvement in ventilatory support (Kirby index of 187). On Day 9, we discontinued azithromycin, and after 14 days lopinavir/ritonavir.

On Day 15, the patient had a fever, and we suspected a ventilator-associated pneumonia. We obtained a tracheal aspirate culture, which showed *Klebsiella pneumoniae*, and we started meropenem for 7 days. After 20 days, clinical, ventilatory, and laboratory parameters

(3.5–5 g/dL), lactate dehydrogenase (LDH) 528 U/L (125–243 U/L), sodium 139 mEq/L (136–145 mEq/L), potassium 3.7 mEq/L (3.5–5.1 mEq/L), chloride 98.2 mEq/L (98–107 mEq/L), and fibrinogen 551 mg/dL (238–498 mg/dL).

Biomarkers revealed a DD of 31.2 mcg/mL (<0.5 mcg/mL), BNP 101 pg/mL (<100 pg/mL), high-sensitivity troponin I (hs-cTnI) 49.7 ng/L (<2 ng/L) (Figure 5), high-sensitivity protein C 22.68 mg/dl (0.00–0.50 mg/dL), ferritin 304 ng/mL (20–250 ng/mL), and procalcitonin 0.55 ng/mL (<0.5 ng/mL). Based on risk factors, clinical presentation, a very high-risk pulmonary embolism severity index (PESI) score (239 points), and high-risk sPESI score (3 points), chest X-ray, biomarkers, and echocardiographic findings, we established a high-clinical suspicion of massive PE and community-acquired pneumonia.

**Figure 2** Chest X-ray that shows bilateral ground-glass opacity and pulmonary infiltrates.

**Video 1** Transthoracic echocardiogram four-chamber view shown right ventricular dysfunction, hypokinesis, and McConell sign.
improved (Figure 5), and we successfully removed the patient from mechanical ventilation.

The patient remained in hospital with episodes of delirium and intermittent dry cough, with oxygen saturation of 98% and ongoing enoxaparin 80 mg BID. A repeat rt-PCR swab was negative for SARS-CoV-2 and negative anti-cardiolipin IgM, IgG, Beta-2-glycoprotein antibodies, and phosphatidylserine IgA, IgM, and IgG were reported. We did not perform lower limb ultrasound and further CTPA due to critical illness.

After 29 days, the patient was discharged with propranolol 10 mg TID, losartan 50 mg BID, amlodipine 5 mg QD, and rivaroxaban 20 mg QD. In a telemedicine follow-up office visit 15 days later, the patient remained asymptomatic and was undergoing physical rehabilitation. A follow-up echocardiogram performed four months after initial presentation showed improvement in right ventricular size and function, with a TAPSE of 23 mm (Video 2).
Discussion

The main observations of this case were as follows: firstly, after thrombolysis and anticoagulation, DD measurements improved. Secondly, upon admission BNP was discordantly low despite severe right ventricular dysfunction, likely related to a short time between the onset of symptoms and admission to hospital; in the next 24 h BNP correlated with the presence and degree of right ventricular dysfunction and higher hs-cTnI measurements, suggesting type 2 myocardial infarction. Thirdly, this case was a clinical challenge because acute PE and COVID-19 pneumonia overlapped. Finally, this case represents—to our knowledge—the first description of biomarkers (DD, BNP, hs-cTnI) in scenarios involving COVID-19 pneumonia and PE.

Since the first clinical description, abnormal DD measurements and age have been related to increased mortality and a high prevalence of thrombotic events in COVID-19. Patients with severe COVID-19 disease are at high-risk of thromboinflammation since they have proinflammatory risk factors and cardiopulmonary comorbidities related to inflammation. The SARS-CoV-2 infection leads to a cytokine storm, inducing endothelial activation, cell damage, increased platelet aggregation, thrombi sensitivity, arterial inflammation, as well as disruption of vulnerable plaques. Interleukin-6 (IL-6) induces the expression of several prothrombotic factors and dysregulation of antithrombin III, protein S, and thrombomodulin. Additionally, it could activate immunothrombosis, another thrombosis mechanism. All these mechanisms can induce diffuse microangiopathy with micro and macro thrombosis. Also, SARS-CoV-2 may predispose to both venous and arterial thrombosis secondary to antiphospholipid antibodies, hypoxia, immobilization, and diffuse intravascular coagulation.

Among the common complications observed in deceased patients with severe COVID-19, venous thromboembolism (VTE) has emerged as a critical and frequent complication. Currently, we do not have strong evidence of the overall incidence and recommendations for in-hospital anticoagulation in patients with PE. However, the available evidence suggests a frequency of 25% to 27% in ICU patients and imaging has demonstrated both unilateral and bilateral thrombus (small branches, segmental, lobar, and main pulmonary artery). DD measurements seem to be an available test to identify high-risk groups of VTE and patients that need different doses of enoxaparin (low (0.6 mg/kg/12 h) or standard treatment). In this complicated case with overlapping severe COVID-19 pneumonia and PE, the clinical presentation suggesting massive PE drove the decision to use systemic thrombolysis. We supported the high-clinical suspicion of massive PE based on sudden dyspnoea, chest pain, presyncope, a fall in blood pressure, ECG changes, echocardiographic findings, as well as signs of deep venous thrombosis. We decided to interrupt the alteplase infusion based on thrombus burden, which was lower than expected considering the clinical presentation of massive PE, a high rate of bleeding (16%) in populations with respiratory failure and lacking recommendations in severe COVID-19 disease. A relevant observation is that after the alteplase bolus, an immediate significant clinical improvement suggesting reperfusion appeared. This result could represent the effectiveness and safety of 10 mg or 5 mg alteplase bolus to initiate fibrinolysis in ST-elevation myocardial infarction and left atrial thrombus, respectively. Also, another low dose of alteplase (30 mg) was safe and effective in submassive PE patients, and an alteplase bolus of 10 mg followed by a 2-h 40 mg infusion in ARDS and pulmonary vascular phenotype COVID-19 patients.

**Figure 4** Chest computed tomography. (A) A classic crazy-paving pattern, with extensive bilateral ground-glass opacities in middle and lower lobes. Upper lobes extension of the aforementioned opacities is depicted in (B).
After thrombolysis, in the first 96 h, enoxaparin achieved a significant decrease in DD measurements (Figure 5). Considering the clinical condition, the evidence suggesting prophylactic anticoagulation failure,24 and the high risk of recurrence (individual, COVID-19, ICU, and hospital stay), we sustained the subcutaneous therapeutic anticoagulation without bleeding complications during the in-hospital stay. At admission, the exceptionally high DD levels observed suggested hyper-inflammation, hypercoagulability, and an actual thrombotic disease, possibly induced by cellular activation triggered by the virus,25 and resemble the extremely high values encountered in COVID-19 related acute or pulmonary,26 as well as thrombotic events in cerebral27 and coronary circulation.28 Additionally, we should never ignore abnormal or extremely elevated DD levels29 in COVID-19, since it is the expression of the coagulation system and fibrinolysis activity, suggesting high-risk of acute thrombosis.29 Although, in our case, the extremely elevated DD levels could be explained by the association of severe COVID-19 and VTE, we cannot exclude the possibility of subclinical cancer.30 After anticoagulation therapy, reduced DD levels suggest anticoagulation effectiveness16 (Figure 5). Preliminary evidence suggests mortality benefit from anticoagulation in severe COVID-19 disease,31 including anti-inflammatory mechanisms.32 Upon admission, the measurement of hs-cTnl suggested myocardial injury with a subsequent increase (likely due to type 2 myocardial infarction) still detectable until 96 h later (Figure 5), similar to the behaviour observed in PE patients.33 The initial therapeutic approach decreased the expression of hs-cTnl, which is historically related to poor in-hospital outcomes in COVID-1915 and non-COVID-19 patients.3 Another interesting finding was the initial borderline BNP measurements despite severe RVD. B-type natriuretic peptide concentration might seem discordantly low in flash pulmonary oedema (1 h), acute pulmonary oedema secondary to acute mitral regurgitation, immunologic myopericarditis with predominantly right ventricular involvement34 and submassive PE.35 In these settings, BNP gene expression may have had insufficient time between the initial trigger of increased ventricular wall stress and the measurement of BNP concentrations, since the half-life of BNP is 23 min and 2 h are required for its full expression.35 The mechanism of massive PE and initial almost normal BNP value was the immediate patient presentation after symptom onset.35 This case identifies another clinical condition characterized by severe ventricular dysfunction and discordantly low BNP. BNP measurements in the next 24 h correlated with the right ventricular dysfunction stage and reperfusion,36 and serial measurements were useful in assessing the success of thrombolysis and anticoagulation.36 Despite worsening respiratory effects and mechanical ventilation, BNP remained below 50 pg/mL until discharge (Figure 5).

Non-COVID-19 pneumonia and PE have a frequent association (65.6%) that increases mortality.37 This patient with risk factors for PE and risk factors for severe COVID-19 disease had both acute events at home. Current evidence regarding COVID-19 pneumonia and PE comes from in-hospital series and case reports.3,5,14,17,18,26,38–40 Therefore, the clinical presentation of an acute PE in the setting of
severe COVID-19 pneumonia in an outpatient is not clear. Recently, in a case series of PE patients with risk factors, the clinical presentation was characterized by persistence or worsening of respiratory symptoms with increasing oxygen requirements. Besides, DD levels were several-fold higher than the normal upper threshold. Recently, systemic thrombolysis in one massive PE patient with COVID-19 induced bleeding complications as the cause of mortality; however, the thrombotic regimen and the bleeding complication were not described. Initial clinical behaviour in this case was similar to that observed in non-COVID-19 submassive and massive PE patients. Considering CTPA findings, the mechanisms of pulmonary hypertension and right ventricular dysfunction could be multifactorial, including pulmonary thrombi, hypoxic pulmonary vasoconstriction, and possible pulmonary microthrombi. Also, SARS-CoV-2 direct downregulation of ACE2 may result in unopposed angiotensin II accumulation and local renin-angiotensin-aldosterone system (RAAS) activation, increasing pulmonary vasoconstriction. Finally, the favourable regulation of ACE2 may result in unopposed angiotensin II accumulation and local renin-angiotensin-aldosterone system (RAAS) activation, increasing pulmonary vasoconstriction. Finally, the favourable outcome was related to early PE diagnosis and a multimodal therapeutic approach, including respiratory support, fibrinolysis activation, coagulation system inhibition, antivirals, antibiotics, a monoclonal antibody, and hyperimmune plasma (Figure 5). We also need current and robust evidence to identify if we need a different thrombotic regimen to those currently recommended.

Conclusion

Physicians in the ER should be warned about high or extremely elevated DD measurements and severe oxygen desaturation, as possible risk markers of severe COVID-19 pneumonia in patients with high clinical suspicion of PE. Also, they should be aware of this 2-h lag period before the onset of BNP increase to avoid underdiagnosing right ventricular dysfunction. Finally, we suggest CTPA before starting immediate reperfusion in a severe COVID-19 patient with high clinical suspicion of massive PE.

Lead author biography

Héctor Betancourt-del Campo is a Cardiology Fellow in training and has an Internal Medicine PhD. He actually practices echocardiography, heart failure, haemodynamics, and electrophysiology in Zambrano Helion Hospital, TecSalud of Tecnologico de Monterrey. He is interested in becoming an Electrophysiology Fellow next year.

Slide sets: A fully edited slide set detailing this case and suitable for local presentation is available online as Supplementary data.

Consent: The author(s) confirm that written consent for submission and publication of this case report including image(s) and associated text has been obtained from the patient in line with COPE guidelines.

Conflict of interest: none declared.

Funding: none declared.

References

1. Ellingshaus D, Degenhardt F, Bujanda L, Buti M, Albillos A, Invernizzi P et al. Genomewide association study of severe Covid-19 with respiratory failure. N Engl J Med 2020.
2. Faggiano P, Bonelli A, Paris S, Milesi G, Bisegea S, Bernardi N et al. Acute pulmonary embolism in COVID-19 disease: preliminary report on seven patients. Int J Cardiol 2020;313:129–131.
3. JANUZI JL, MAHLER SA, CHRISTENSON RH, RYMER J, NEWBLY LK, BODY R et al. Recommendations for institutions transitioning to high-sensitivity troponin testing. J Am Coll Cardiol 2019;73:1059–1077.
4. ZHOU F, YU T, DU K, FAN G, LIU Y, LIU Z et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–1062.
5. DANZI GB, LOFFI M, GALEAZZI G, GERBERSI E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur Heart J 2020;41:1858–1858.
6. XIE Y, WANG X, YANG P, ZHANG S. COVID-19 complicated by acute pulmonary embolism. Radiology 2020;2:200067.
7. CHEN T, WU D, CHEN H, YAN W, YANG D, CHEN G et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020;368:
8. Musher DM, Abers MS, Corrales-Medina VF. Acute infection and myocardial infarction. N Engl J Med 2019;380:171–176.
9. ATRI D, SIDDIQI HK, LANG J, NAUFFAL V, MORROW DA, BOHULA EA. COVID-19 for the cardiologist: a current review of the virology, clinical epidemiology, cardiac and other clinical manifestations and potential therapeutic strategies. JACC Basic Transl Sci 2020;5:518–536.
10. VAZQUEZ-GARZA E, JEREZ-SANCHEZ C, NAVARRETE A, JOYA-HARRISON J, RODRIGUEZ D. Venous thromboembolism: thrombosis, inflammation, and immunothrombosis for clinicians. J Thromb Thrombolysis 2017;44:377–385.
11. LIU PP, BLAT A, SMYTH D, LI H. The science underlying COVID-19: implications for the cardiovascular system. Circulation 2020;142:68–78.
12. ZHANG Y, XIAO M, ZHANG S, XIA P, CAO W, JIANG W et al. Coagulopathy and anti-phospholipid antibodies in patients with Covid-19. N Engl J Med 2020;382:e38.
13. BOWLES L, PLATTO N, YARNEY N, DAVE M, LEE K, HART DP et al. Lupus anticoagulant and abnormal coagulation tests in patients with Covid-19. N Engl J Med 2020;383:288–290.
14. KLOK FA, KRUP MJH, VAN DER MEER NJM, ARBOUS MS, GOMMERS D, KANT KM et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020;191:148–150.
15. BIKDELI B, MADHAVAN PV, JIMENEZ D, CHUICH T, DREYFUSS L, DRIGGIN E et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol 2020;75:2950–2973.
16. CUI S, CHEN S, LI X, LIU S, WANG F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thorac Haemost 2020;18:1421–1424.
17. ULLEH W, SAEED R, SARWAR U, PATEL R, FISCHMAN DL. COVID-19 complicated by acute pulmonary embolism and right-sided heart failure. JACC Case Rep 2020;2:1379–1382.
18. CHEN J, WANG X, ZHANG S, LIU B, WU X, WANG Y et al. Findings of acute pulmonary embolism in COVID-19 patients. SSRN 2020.
19. GUREWICH V. Therapeutic fibrinolysis. J Am Coll Cardiol 2016;68:2099–2106.
20. WOLFF G, KELM M, WESTERFELD R, HORN P. Low-dose thrombolysis for the management of left atrial thrombus formation during percutaneous mitral valve repair. JACC Cardiovasc Interv 2019;12:e9–10-e10.

Supplementary material

Supplementary material is available at European Heart Journal - Case Reports online.